Results of evaluation of the effectiveness of the drug Cellex in patients with small vessel disease
- 2 February 2023
- journal article
- research article
- Published by Media Sphere Publishing Group in Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova
- Vol. 123 (1), 67-74
- https://doi.org/10.17116/jnevro202312301167
Abstract
To study the effect of the drug Cellex on the severity of cognitive impairment in patients with small vessel disease (SVD). A non-interventional observational controlled prospective observational study in parallel groups was conducted. 118 patients with CHEM who received unified therapy were under observation. Group 1 consisted of 40 patients who, in addition to basic therapy, received 10 injections of Cellex subcutaneously (0.2 ml 1 time/day), group 2 — 39 patients who received 2 courses of injections of Cellex subcutaneously (0.1 ml 1 time/day) with an interval of one month, patients 3-both groups (n=39) received only basic therapy. The examination included an assessment of the clinical status and neuropsychological testing (the MOS questionnaire and the clock drawing test — TRCH), analysis of the results of MRI of the brain. The blood levels of homocysteine (HC), C-reactive protein (CRP), asymmetric dimethylarginin (ADMA), and von Willebrand factor (FW) were determined in dynamics. A statistically significant improvement in the performance of the MoCA and TRP questionnaire tests in groups 1 and 2 was demonstrated, with a more pronounced and persistent effect in patients who received repeated courses of treatment. Clinical improvement was accompanied by normalization of the concentration of studied markers of inflammation (CRP) and endothelial dysfunction (HC, ADMA, FW) in the blood, while the dynamics was most pronounced in patients of group 2. The treatment was characterized by good tolerability, low frequency and insignificant severity of adverse events. The drug Cellex has demonstrated significant effectiveness in the treatment of patients with SVD with cognitive impairment, against the background of treatment, there was a decrease in markers of inflammation and endothelial dysfunction, therapy was characterized by good tolerability.Keywords
This publication has 8 references indexed in Scilit:
- Association of inflammatory markers with cerebral small vessel disease in community-based populationJournal of Neuroinflammation, 2022
- Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet Neurology, 2021
- Epidemiology and prognosis of the level of morbidity and mortality from stroke in different age groups according to the territorial-population registerZhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2019
- Actual problems of brain pathology in cerebral microangiopathyZhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2018
- Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementiaClinical Science, 2017
- The effect of cellex on cognitive and speech impairments in the acute stage of strokeZhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2015
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationThe Lancet Neurology, 2013
- Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challengesThe Lancet Neurology, 2010